Key Highlights

  • SXTP traded lower at last closing, a sub-dollar Nasdaq nano-cap with a market cap of only a few million dollars.
  • The company achieved minimum enrollment in its hospitalized babesiosis study, with an interim readout expected by October 6, 2026.
  • An independent Data Safety Monitoring Board recommended continuation of its B-Free chronic babesiosis study on July 1, 2026.
  • 60 Degrees priced a private Placement of shares and warrants on July 30, 2026, ahead of a September investor conference.

A busy summer of clinical and financing announcements has kept 60 Degrees Pharmaceuticals, Inc (NASDAQ:SXTP) in the conversation among small-cap biotech watchers, even as the shares trade below a dollar. The Washington, D.C.-area infectious-disease specialist is best known for antiparasitic work, and it heads into the second half of 2026 with a near-term data readout on the calendar and an investor-conference appearance scheduled. A single soft session has not changed that setup, but it underscores how volatile a sub-dollar micro-cap can be.

Company and Latest Development

60 Degrees Pharmaceuticals develops therapies for infectious diseases, with a portfolio rooted in antimalarial and tick-borne-disease research. The company's most closely watched program targets babesiosis, a tick-borne parasitic infection. On July 29, 2026, 60 Degrees said it had achieved minimum enrollment in its study of hospitalized babesiosis patients and pointed to an interim data readout expected by October 6, 2026. Days earlier, on July 1, an independent Data Safety Monitoring Board recommended continuation of its B-Free chronic babesiosis study. The company also disclosed, on July 8, an exclusive option agreement with Florida State University to develop castanospermine for tick-borne diseases, broadening its early-stage pipeline.

What Is Driving Attention Around SXTP?

The modest single-day decline noted at last closing does not tie to a confirmed, same-session catalyst. Sub-dollar Nasdaq names move sharply on light volume, and small percentage swings frequently reflect trading dynamics rather than fresh disclosures. The substantive drivers of attention are the pending babesiosis interim readout and a stretch of corporate activity: 60 Degrees released second-quarter 2026 results on August 14, filed a registration statement for a securities offering, and completed a private placement of shares and warrants priced at market on July 30. It is also slated to present at H.C. Wainwright's 28th Annual Global Investment Conference, with meetings in mid-September.

Key Numbers and Company Position

60 Degrees trades on the Nasdaq under SXTP as a sub-dollar stock with a market Capitalization of only a few million dollars, placing it firmly in nano-cap territory. Consistent with that profile, the company has turned to dilutive financing, including the July 30 private placement of shares and warrants and a registration statement enabling further capital raising. Investors should treat any single quoted figure cautiously; the company's SEC filings and quarterly results remain the authoritative source for verified revenue, cash and share-count detail rather than intraday market-data snapshots.

What Could Come Next?

The clearest near-term catalyst is the babesiosis interim data readout flagged for on or before October 6, 2026, which could meaningfully influence sentiment. Continued progress in the B-Free chronic babesiosis study, updates on the Florida State castanospermine option, and management's presentations at the September H.C. Wainwright conference are additional developments to monitor. Given the company's small cash base, any further financing announcements would also be watched closely.

Risks to Watch

The risks are substantial. Clinical readouts can disappoint, and interim data may not translate into successful pivotal results or regulatory approval. As a nano-cap that has repeatedly raised capital, 60 Degrees carries meaningful dilution and funding risk, and its sub-dollar share price raises the prospect of Nasdaq listing-compliance concerns if weakness persists. Competition in infectious disease, commercialization uncertainty and thin Liquidity round out the risk picture.

A Defined Catalyst on the October Calendar

60 Degrees Pharmaceuticals enters the fourth quarter of 2026 with a defined catalyst in view: interim babesiosis data expected by early October. Paired with recent financings, a new research option and a September investor-conference slot, the setup gives SXTP a busier narrative than its tiny valuation might suggest.